Clinical Trials as Potentially Invalidating Public Uses: Current Issues and Future Questions Under the Leahy-Smith America Invents Act

more+
less-

Originally published in BNA’s Patent, Trademark & Copyright Journal on 09/28/2012.

When is a clinical trial an invalidating public use of an invention? Courts have struggled with this question — one particularly important in the pharmaceutical, biotechnology, and medical device industries — for years

Patent protection is one of the primary reasons investors are willing to risk money in developing new pharmaceuticals and medical devices. However, U.S. patent law prohibits an inventor from obtaining a patent on any invention that was in ‘‘public use’’ more than one year before the application leading to the patent was filed, unless the use was primarily experimental in nature.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  America Invents Act, Clinical Trials, Patent Reform, Patents, Pharmaceutical, Public Use

Published In: Administrative Agency Updates, Intellectual Property Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Loeb & Loeb LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »